We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Viatris
VTRS
$20.1B
| $261K | ﹤0.01% |
26,119
-176
| -0.7% | -$1.68K |
|
602
Invesco BuyBack Achievers ETF
PKW
$1.69B
| $259K | ﹤0.01% |
2,900
| – | – |
|
603
AZZ Inc
AZZ
$4.5B
| $258K | ﹤0.01% |
+5,945
| New | +$228K |
|
604
Uber
UBER
$134B
| $258K | ﹤0.01% |
5,980
| – | – |
|
605
Cadence Design Systems
CDNS
$90B
| $257K | ﹤0.01% |
1,097
+28
| +3% | +$6.09K |
|
606
AeroVironment
AVAV
$7.57B
| $257K | ﹤0.01% |
2,512
| – | – |
|
607
D.R. Horton
DHI
$41B
| $256K | ﹤0.01% |
2,100
-241
| -10% | -$26.4K |
|
608
Broadridge
BR
$17.2B
| $253K | ﹤0.01% |
1,527
| – | – |
|
|
MAGN
609
Magnera Corp
MAGN
$488M
| $251K | ﹤0.01% |
6,400
-12
| -0.2% | -$544 |
|
610
Progressive
PGR
$124B
| $241K | ﹤0.01% |
1,820
| – | – |
|
611
Coherent
COHR
$55.2B
| $241K | ﹤0.01% |
4,725
| – | – |
|
|
JBGS
612
JBG SMITH
JBGS
$846M
| $239K | ﹤0.01% |
15,909
| – | – |
|
613
iShares Russell Mid-Cap ETF
IWR
$56.8B
| $239K | ﹤0.01% |
3,266
+1,365
| +72% | +$94.9K |
|
614
Labcorp
LH
$24.3B
| $237K | ﹤0.01% |
1,141
| – | – |
|
|
SASR
615
DELISTED
Sandy Spring Bancorp Inc
SASR
| $235K | ﹤0.01% |
10,347
-4,473
| -30% | -$103K |
|
616
Darden Restaurants
DRI
$22.5B
| $233K | ﹤0.01% |
1,395
+66
| +5% | +$10.4K |
|
617
Thor Industries
THO
$3.99B
| $233K | ﹤0.01% |
+2,250
| New | +$190K |
|
618
Truist Financial
TFC
$63.2B
| $232K | ﹤0.01% |
7,658
| – | – |
|
619
OP Bancorp
OPBK
$233M
| $232K | ﹤0.01% |
27,500
+5,000
| +22% | +$42.3K |
|
620
Invesco DB Commodity Index Tracking Fund
DBC
$1.73B
| $232K | ﹤0.01% |
10,200
-39,000
| -79% | -$904K |
|
621
SAB Biotherapeutics
SABS
$268M
| $231K | ﹤0.01% |
27,778
| – | – |
|
622
Idexx Laboratories
IDXX
$42.9B
| $229K | ﹤0.01% |
455
-36,430
| -99% | -$17.5M |
|
623
L3Harris
LHX
$55.9B
| $228K | ﹤0.01% |
1,166
-150
| -11% | -$28.7K |
|
624
NOV
NOV
$7.45B
| $228K | ﹤0.01% |
14,187
| – | – |
|
625
WD-40
WDFC
$3.1B
| $226K | ﹤0.01% |
1,200
-100
| -8% | -$18.9K |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.